← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › QUINOLONE ANTIBACTERIALS › Fluoroquinolones
delafloxacin
J01MA23
Forms & Strengths
- Tablet: 450 mg
- Injection: 300 mg single-dose vial
Adult Dosing
- Acute bacterial skin and skin structure infections (ABSSSI): 300 mg IV every 12 hours or 450 mg oral every 12 hours for 5 to 14 days
- Community-acquired bacterial pneumonia (CABP): 300 mg IV every 12 hours or 450 mg oral every 12 hours for 5 to 7 days
- Renal impairment adjustment: No dosage adjustment needed for mild, moderate, or severe renal impairment (IV or oral)
Pediatric Dosing
- Safety and efficacy in pediatric patients below 18 years of age have not been established
Indications
- Treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive and Gram-negative organisms
- Treatment of community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms
Mechanism of Action
- Fluoroquinolone antibacterial agent that inhibits bacterial topoisomerase IV and DNA gyrase, enzymes essential for bacterial DNA replication, transcription, repair, and recombination
Contraindications
- Known hypersensitivity to delafloxacin or other fluoroquinolones
- History of fluoroquinolone-associated tendinitis and tendon rupture
Adverse Reactions
- Nausea
- Diarrhea
- Headache
- Transaminases increased
- Vomiting
- Black box warnings: Tendinitis, tendon rupture, peripheral neuropathy, central nervous system effects, and exacerbation of myasthenia gravis
Drug Interactions
- Chelating agents: Multivalent cation-containing products (antacids, sucralfate, metal cations) interfere with oral absorption; administer oral delafloxacin 2 hours before or 6 hours after
- Drugs known to prolong QT interval: Use with caution as fluoroquinolones may cause additive QT prolongation
Curated Content: Needs Vetting Before Put to Clinical Use